For research use only. Not for therapeutic Use.
SHEN26 (Cat No.: I040127) is a small-molecule compound under investigation for its potential therapeutic properties, particularly in cancer and inflammation research. It has been identified for its ability to modulate specific cellular pathways, such as cell proliferation and apoptosis, through targeted inhibition of key enzymes or receptors. Preclinical studies suggest that SHEN26 may have anticancer effects, possibly by interfering with tumor cell survival or metastasis. Additionally, it may show promise in regulating immune responses, offering potential for treating autoimmune disorders or inflammatory diseases.
| CAS Number | 2691076-98-7 |
| Synonyms | [(2R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl cyclohexanecarboxylate |
| Molecular Formula | C19H23N5O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H23N5O5/c20-9-19(14-7-6-12-17(21)22-10-23-24(12)14)16(26)15(25)13(29-19)8-28-18(27)11-4-2-1-3-5-11/h6-7,10-11,13,15-16,25-26H,1-5,8H2,(H2,21,22,23)/t13-,15?,16+,19+/m1/s1 |
| InChIKey | NJZZWWHRMAGFGB-TVMOFBLASA-N |
| SMILES | C1CCC(CC1)C(=O)OCC2C(C(C(O2)(C#N)C3=CC=C4N3N=CN=C4N)O)O |
| Reference | [1]. Chen Q, et al. Optimized Kilogram-Scale Synthesis and Impurity Identification of SHEN26 (ATV014) for Treating COVID-19. Organic Process Research & Development. 2023 Nov 20. [2]. Ji X, et al. Research and development of Chinese anti-COVID-19 drugs. Acta Pharm Sin B. 2022 Dec;12(12):4271-4286. |
